(Q33332750)

25 July 2017

title

A phase I trial of docetaxel and gemcitabine in patients with advanced cancer (English)

1 reference

25 July 2017

main subject

phase I clinical trial

0 references

1 reference

M Boyer

2

0 references

author name string

D Rischin

1

1 reference

25 July 2017

J Smith

3

1 reference

25 July 2017

M Millward

4

1 reference

25 July 2017

M Michael

5

1 reference

25 July 2017

J Bishop

6

1 reference

25 July 2017

J Zalcberg

7

1 reference

25 July 2017

J Davison

8

1 reference

25 July 2017

E Emmett

9

1 reference

25 July 2017

B McClure

10

1 reference

25 July 2017

publication date

1 April 2000

1 reference

25 July 2017

1 reference

25 July 2017

volume

11

1 reference

25 July 2017

issue

4

1 reference

25 July 2017

page(s)

421-426

1 reference

Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008384326701

7 January 2021

Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008384326701

7 January 2021

Advanced breast cancer: a phase II trial with gemcitabine

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008384326701

7 January 2021

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008384326701

7 January 2021

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008384326701

7 January 2021

Docetaxel delivers new management opportunities for gastrointestinal carcinomas.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008384326701

7 January 2021

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008384326701

7 January 2021

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008384326701

7 January 2021

Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008384326701

7 January 2021

Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008384326701

7 January 2021

Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008384326701

7 January 2021

Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer: usefulness of mathematic modeling to determine maximum-tolerable dose

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008384326701

7 January 2021

Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008384326701

7 January 2021

Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008384326701

7 January 2021

Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008384326701

7 January 2021

Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008384326701

7 January 2021

Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008384326701

7 January 2021

Identifiers

DOI

10.1023/A:1008384326701

1 reference

25 July 2017

1 reference